Kyverna Therapeutics
KYTXKYTX · Stock Price
Historical price data
Overview
Kyverna Therapeutics is a clinical-stage biotech company with a mission to liberate autoimmune patients through the curative potential of engineered cell therapies. Founded in 2018 and publicly listed in 2024, the company has rapidly advanced its clinical pipeline, having treated over 100 patients across multiple autoimmune indications. Its strategy centers on translating the proven success of CD19-targeting CAR T-cells from oncology to autoimmunity, aiming to achieve deep B-cell depletion, immune reset, and long-term, treatment-free remission.
Technology Platform
A proprietary platform for engineered CAR T-cell therapies targeting CD19 on B cells, featuring a fully human CAR construct with a CD28 co-stimulatory domain designed for improved tolerability, and supporting both autologous and allogeneic manufacturing approaches.
Pipeline
12| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Standard of Care Treatment + Standard lymphodepletion regime... | Myasthenia Gravis | Phase 2/3 | |
| Standard lymphodepletion regimen | Stiff-Person Syndrome | Phase 2 | |
| KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mAB | Multiple Sclerosis, Primary Progressive | Phase 2 | |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immu... | ANCA-IgG-positive ANCA Associated Vasculitis | Phase 1/2 | |
| KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodeplet... | Lupus Nephritis | Phase 1/2 |
Funding History
5
Company Timeline
Founded in Emeryville, United States
IPO — $319.0M
Series D: $319.0M
Series C: $319.0M